About: Incidence of COVID‐19 in patients with rheumatic diseases treated with targeted immunosuppressive drugs: what can we learn from observational data?

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Incidence of COVID‐19 in patients with rheumatic diseases treated with targeted immunosuppressive drugs: what can we learn from observational data? Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Incidence of COVID‐19 in patients with rheumatic diseases treated with targeted immunosuppressive drugs: what can we learn from observational data?
Creator	Caporali, Roberto Favalli, Ennio Ingegnoli, Francesca Balduzzi, Silvia Montecucco, Carlomaurizio Monti, Sara Giulio Favalli, Ennio
Source	Medline; PMC
abstract	OBJECTIVES: To describe the incidence and severity of coronavirus disease 2019 (COVID‐19) in rheumatic patients treated with targeted synthetic or biological anti‐rheumatic drugs (ts/bDMARDs) compared with the general population living in the same Italian region. METHODS: Patients followed at two referral rheumatology centres in Lombardy from 25(th) February to 10(th) April 2020 were invited to participate in a survey to detect patients with confirmed COVID‐19, close contacts with known COVID‐19 cases, symptoms of infection, working, behavioural and disease management changes applied to prevent the contagion. The incidence of COVID‐19 in the Lombardy population was obtained from the National Institute of Statistics. Confirmed COVID‐19 was defined by nasopharyngeal swab. RESULTS: The survey was circulated amongst 955 patients (531 rheumatoid arthritis, 203 psoriatic arthritis, 181 spondyloarthritis, and 40 of connective tissue diseases/vasculitides/autoinflammatory diseases; mean age 53.7 years; female: 67.4%). The rate of responders was 98.05%. The incidence of confirmed COVID‐19 is consistent with the general population (0.62% vs 0.66%; p=0.92). None of the patients had severe complications or required intensive care treatment, and all of them temporarily discontinued ongoing ts/bDMARDs therapy. Almost all patients adopted precautions to prevent the contagion (90.6%) and maintained the ongoing treatment with ts/bDMARDs (93.2%). The disease activity remained stable in 89.5% of patients. CONCLUSIONS: Our results highlight the attitude from rheumatic patients to prevent the contagion while maintaining their chronic treatments. The incidence and severity of COVID‐19 in patients treated with ts/bDMARDs was not significantly different from that of the general population in the same region.
has issue date	2020-06-07(xsd:dateTime)
bibo:doi	10.1002/art.41388
bibo:pmid	32506699
has license	no-cc
sha1sum (hex)	980b04ea484bc13612d13b2d5269f2f8a4862364
schema:url	https://doi.org/10.1002/art.41388
resource representing a document's title	Incidence of COVID‐19 in patients with rheumatic diseases treated with targeted immunosuppressive drugs: what can we learn from observational data?
has PubMed Central identifier	PMC7300434
has PubMed identifier	32506699
schema:publication	Arthritis Rheumatol
resource representing a document's body	covid:980b04ea484bc13612d13b2d5269f2f8a4862364#body_text
is schema:about of	named entity 'learn' covid:arg/980b04ea484bc13612d13b2d5269f2f8a4862364 named entity 'rheumatic' named entity 'living' named entity 'rheumatic diseases' named entity 'Lombardy' named entity 'SARS-CoV-2' named entity 'Descriptive statistics' named entity 'smokers' named entity 'final analysis' named entity 'etanercept' named entity 'rheumatological' named entity 'DMARDs' named entity 'interquartile range' named entity 'observational study' named entity 'nasopharyngeal swab' named entity 'study population' named entity 'iatrogenic' named entity 'Lombardy' named entity 'secukinumab' named entity 'COVID' named entity 'study population' named entity 'face masks' named entity 'nasopharyngeal swabs' named entity 'sarcoidosis' named entity 'epidemic' named entity 'general population' named entity 'COVID' named entity 'general population' named entity 'SARS-CoV-2' named entity 'SPSS' named entity 'COVID' named entity '95% confidence interval' named entity 'COVID-19' named entity 'COVID' named entity 'COVID-19 outbreak in Italy' named entity 'infection' named entity 'rheumatologic disease' named entity 'study population' named entity 'specialist doctor' named entity 'monotherapy' named entity 'rheumatologic' named entity 'March 2020' named entity 'antiviral effect' named entity 'COVID' named entity 'tocilizumab' named entity 'rheumatologist' named entity 'immunosuppressive therapy' named entity 'disease-modifying' named entity 'case series' named entity 'infection' named entity 'COVID-19 outbreak' named entity 'influenza' named entity 'tested for COVID-19' named entity 'Italian' named entity 'infection' named entity 'general population' named entity 'animal origin' named entity 'endocytosis' named entity 'immunomodulating' named entity 'Lombardy' named entity 'immunomodulatory' named entity 'Pathogenetically' named entity 'study population' named entity 'biological therapy' named entity 'ARDS' named entity 'intensive care unit' named entity 'COVID' named entity 'SARS-CoV-2' named entity 'COVID' named entity 'COVID-19' named entity 'prognostic' named entity 'rheumatologic disease' named entity 'follow-up' named entity 'comorbidities'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software